EA201991192A1 - Фармацевтические композиции и способы лечения рака - Google Patents

Фармацевтические композиции и способы лечения рака

Info

Publication number
EA201991192A1
EA201991192A1 EA201991192A EA201991192A EA201991192A1 EA 201991192 A1 EA201991192 A1 EA 201991192A1 EA 201991192 A EA201991192 A EA 201991192A EA 201991192 A EA201991192 A EA 201991192A EA 201991192 A1 EA201991192 A1 EA 201991192A1
Authority
EA
Eurasian Patent Office
Prior art keywords
promoter
methods
inhibitor
subject
melanin
Prior art date
Application number
EA201991192A
Other languages
English (en)
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/351,966 external-priority patent/US10272068B2/en
Application filed filed Critical
Publication of EA201991192A1 publication Critical patent/EA201991192A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
EA201991192A 2016-11-15 2017-11-15 Фармацевтические композиции и способы лечения рака EA201991192A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/351,966 US10272068B2 (en) 2012-01-17 2016-11-15 Pharmaceutical compositions and methods
PCT/US2017/061682 WO2018093820A1 (en) 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
EA201991192A1 true EA201991192A1 (ru) 2019-10-31

Family

ID=60570232

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991192A EA201991192A1 (ru) 2016-11-15 2017-11-15 Фармацевтические композиции и способы лечения рака

Country Status (12)

Country Link
EP (1) EP3541411A1 (enExample)
JP (2) JP2019537608A (enExample)
KR (2) KR20190084291A (enExample)
CN (1) CN110167580A (enExample)
AU (1) AU2017361080A1 (enExample)
BR (1) BR112019009799A2 (enExample)
CA (1) CA3040922A1 (enExample)
EA (1) EA201991192A1 (enExample)
IL (1) IL266486A (enExample)
MX (1) MX2019005450A (enExample)
PH (1) PH12019500758A1 (enExample)
WO (1) WO2018093820A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US20210106549A1 (en) * 2019-10-15 2021-04-15 Tyme, Inc. Pharmaceutical compositions and methods
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2022120039A2 (en) * 2020-12-02 2022-06-09 Steven Hoffman Compositions and methods for modulating cancer in non-human mammals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods
US8481498B1 (en) * 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
EP3541411A1 (en) 2019-09-25
KR20190084291A (ko) 2019-07-16
BR112019009799A2 (pt) 2019-08-06
KR20230003314A (ko) 2023-01-05
WO2018093820A1 (en) 2018-05-24
AU2017361080A1 (en) 2019-05-02
CA3040922A1 (en) 2018-05-24
MX2019005450A (es) 2019-07-04
CN110167580A (zh) 2019-08-23
JP2023018029A (ja) 2023-02-07
JP2019537608A (ja) 2019-12-26
PH12019500758A1 (en) 2019-07-24
IL266486A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
MX2024014142A (es) Novedosos inhibidores de molecula peque?a de factores de transcripcion tead
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
ZA202007007B (en) Mcl-1 inhibitors
CL2020002082A1 (es) Inhibidores pd-1/pd-l1.
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
EA201300171A1 (ru) Способы и композиции для терапии рака печени
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX382624B (es) Compuestos farmacéuticos.
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
JOP20230160A1 (ar) مركبات كينولين ومركبات آزا كينولين كمثبطات لـ cd38
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2024002391A (es) Inhibidores de indolina de kif18a.
EP4599893A3 (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
EA201891601A1 (ru) Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201800787B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
EA201991305A1 (ru) Производные тирозина и композиции, включающие их
EA202190201A1 (ru) Составы для уменьшения размера опухоли и способы их применения